Stockscreener 앱 받기
6.57
2.38%
-0.16
시간 외 거래:
6.62
0.05
+0.76%
Profound Medical Corp 주식(PROF)의 최신 뉴스
Profound Medical Corp. (PROF) Gains 1.89% as Key Levels Come into FocusIsland Reversal - newsline.com
Profound Medical Corp. (PROF) Edges Lower as Stock Tests Key Support LevelsBuyback Factor - newsline.com
PROF Q1 2026 Earnings: Narrower Loss Than Expected, Shares Edge LowerEarnings Weakness Phase - newsline.com
Why Profound Medical Corp stock is sliding today - Wealth Awesome
Profound Medical Corp. (PROF) Gains Nearly 4% as Bullish Momentum BuildsSMA Signal - newsline.com
Why Profound Medical Corp stock is rising today - Wealth Awesome
Why Profound Medical Corp stock is tanking today - Wealth Awesome
How (PROF) Movements Inform Risk Allocation Models - Stock Traders Daily
Profound Medical (PROF) Edges Higher Amid Continued Trade Volume and Technical FirmnessTurnaround Stocks - The Legal Advocate
Profound Medical Q1 2026 Earnings: EPS Beats Estimates, Stock DeclinesEarnings Beat Alert - Newser
PROF Q1 2026 Earnings: EPS Surprises to the Upside, Stock Declines 2%Community Pattern Alerts - Newser
Profound Medical (PROF) Hovers Near Support Amid Modest DeclineFactor Momentum - Newser
[EFFECT] Profound Medical Corp. SEC Filing - Stock Titan
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High? - Yahoo Finance
Profound Medical Shareholders Back Board, Question Incentive Plan - The Globe and Mail
Telix partners with EDAP, Profound on prostate imaging tech - Investing.com UK
Profound Medical (NASDAQ: PROF) investors back board, auditor and long‑term incentive units - Stock Titan
Telix to Collaborate With EDAP, Profound Medical to Explore PSMA-PET Imaging in Prostate Cancer Therapies - Moomoo
Profound Medical Showcases TULSA-PRO Integration with PSMA PET Imaging for Prostate Cancer at AUA2026 - Minichart
Profound Medical Q1 earnings call highlights - MSN
How Profound Medical Corp. (PROF) Affects Rotational Strategy Timing - Stock Traders Daily
Profound Medical Highlights TULSA Advances at AUA 2026 - TipRanks
Profound Medical (NASDAQ: PROF) to highlight TULSA and PSMA PET integration at AUA2026 - Stock Titan
Profound to Showcase TULSA-PRO®, the TULSA Procedure™ and the Future of iMRI at AUA2026 - The Manila Times
Imaging combo to sharpen prostate cancer treatment planning - Stock Titan
Profound to Showcase TULSA-PRO®, the TULSA Procedure and the Future of iMRI at AUA2026 - Investing News Network
Nearly 70% of Profound Medical shares vote to support full board slate - Stock Titan
Profound Medical Annual General and Special Meeting of Shareholders Voting Results - TMX Newsfile
TradingKey - TradingKey
Profound Medical (NASDAQ: PROF) registers 921,428 resale shares - Stock Titan
Profound Medical (PROF) price target decreased by 26.77% to 8.49 - MSN
Profound outlines ~$25M 2026 revenue, anticipates FDA clearance for Siemens Free integration by year-end - MSN
Profound Medical Q1 Earnings Call Highlights - TradingView
Profound Medical revenue up 104% in Q1 2026 - Medical Buyer
Profound Medical Corp. (PROF) Investigation: Bronstein, Gewirtz - The National Law Review
Earnings call transcript: Profound Medical beats Q1 2026 forecasts By Investing.com - Investing.com Australia
Earnings call transcript: Profound Medical beats Q1 2026 forecasts - Investing.com
Profound Medical Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Profound Medical : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Profound Medical Reports Strong First Quarter 2026 Financial Results - Investing News Network
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates - marketscreener.com
Profound Medical Issues FY26 Revenue Guidance and Announces Humana Is Now Covering the TULSA Procedure - marketscreener.com
Profound Medical Says Q1 Results Marked By 104% Revenue Growth and "Improved" Operating Performance - marketscreener.com
Profound Medical Q1 Basic and Diluted Net Loss Per Common Share US$0.19, Vs $0.36 a Year Ago - marketscreener.com
Humana starts covering Profound's TULSA procedure as revenue jumps 104% - Stock Titan
Profound Medical (NASDAQ: PROF) doubles Q1 revenue as losses narrow - Stock Titan
Profound Medical (NASDAQ: PROF) posts 104% Q1 2026 revenue growth - Stock Titan
2.43%
자본화:
|
볼륨(24시간):